A team from the California-based population genomics firm Helix, Renown Health, and the University of Nevada School of Medicine has demonstrated the potential for delayed mammography-based screening in women with lower-than-usual breast cancer risk based on pathogenic variant and polygenic risk score (PRS) data.
News
Breast Cancer Incidence Dialed Down in Individuals With Low Genetic Risk
December 29, 2023Helix Partners
Ready to see the whole picture?
Connect with our team to discover how Helix can transform your approach to genomic medicine.